Your browser doesn't support javascript.
loading
Use and effectiveness of PCSK-9 inhibitors in heart diseases: A review.
Alorfi, Nasser M; Harbi, Maan H; El Hajj, Maguy Saffouh; Alayoubi, Samha; Ibrahim, Nihal Abdalla; Alayoubi, Fakhr Z.
Afiliación
  • Alorfi NM; Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Harbi MH; Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
  • El Hajj MS; College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
  • Alayoubi S; Department of Mathematics and Sciences, College of Humanities and Sciences, Prince Sultan University, Riyadh, Saudi Arabia.
  • Ibrahim NA; College of Pharmacy, Ajman University, Ajman, United Arab Emirates.
  • Alayoubi FZ; Center of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.
Medicine (Baltimore) ; 103(36): e39308, 2024 Sep 06.
Article en En | MEDLINE | ID: mdl-39252316
ABSTRACT
Proprotein Convertase Subtilisin/Kexin type-9 (PCSK-9) inhibitors have recently used in the management of different cardiac complications. Several clinical trials demonstrated their effectiveness in patients with hypercholesterolemia. However, the effectiveness of these medications in patients with heart diseases is still controversial. To review and summarize the clinical trials pertaining to the use and effectiveness of PCSK-9 inhibitors in heart diseases and to discuss the pharmacotherapy of these agents. A review was conducted of all clinical trials with PCSK-9 inhibitors for heart diseases registered at ClinicalTrials.gov since inception up to and including January 19th, 2024. These trials were retrieved. Data from these trials were extracted manually, categorized and analyzed. The number of identified clinical trials was 25,371. After screening and excluding irrelevant studies, 12 studies met the search criteria. The majority of these studies were conducted in the US. The total number of patients in these studies was 27,700. Alirocumab and Evolocumab were the most frequently used PCSK-9 inhibitors. This review identified only a few clinical trials on PCSK-9 inhibitors in heart disease patients. Therefore, it is recommended to conduct more randomized controlled clinical trials on PCSK-9 inhibitors in this patient population.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Inhibidores de PCSK9 / Cardiopatías Límite: Humans Idioma: En Revista: Medicine (Baltimore) Año: 2024 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Inhibidores de PCSK9 / Cardiopatías Límite: Humans Idioma: En Revista: Medicine (Baltimore) Año: 2024 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Estados Unidos